[go: up one dir, main page]

PE20021161A1 - DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1) - Google Patents

DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1)

Info

Publication number
PE20021161A1
PE20021161A1 PE2002000241A PE2002000241A PE20021161A1 PE 20021161 A1 PE20021161 A1 PE 20021161A1 PE 2002000241 A PE2002000241 A PE 2002000241A PE 2002000241 A PE2002000241 A PE 2002000241A PE 20021161 A1 PE20021161 A1 PE 20021161A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
phenyl
alcoxyl
hvr1
Prior art date
Application number
PE2002000241A
Other languages
English (en)
Inventor
Andrew James Culshaw
Peter Gull
Hong-Yong Kim
Kaspar Zimmermann
Mahavir Prashad
Yugang Liu
Max Peter Seiler
Allan Hallett
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0107505A external-priority patent/GB0107505D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20021161A1 publication Critical patent/PE20021161A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIDINA DE FORMULA I DONDE R1 Y R2 SON JUNTOS -NHC(SR6)=N-CO-; -R7NC(R8)=NCO-, -N=C(SR9)NR10CO-, -NR11XNR12CO, NHXNH, -NHXN=CR13-, -NHXNHCH2-, -NZNH-, -N=ZNHCH2-, -N=ZNHCON=ZN=CR14-; X ES CO, CS, CO-CO, Z ES N, CR15; R6 ES ALQUILO C1-C4; R7 Y R8 SON H, ALQUILO C1-C4, CICLOALQUILO C3-C8 O FORMAN JUNTOS UN HETEROCICLO DE 5-6 MIEMBROS; R9 Y R10 JUNTOS SON ALQUILENO C1-C4; R11 ES H, ALQUILO C1-C4, FENILO; R12 ES H, NH2, ALQUILO C1-C4, FENILO; R13 ES H, HALOGENO, NH2, ALCOXILO C1-C4; R14 ES H, OH, HALOGENO, NH2, ALQUILO C1-C4, ALCOXILO C1-C4; R15 ES H, HALOGENO, ALQUILO C1-C4, ALCOXILO C1-C4, SCH2COOC(CH3)3; R3 ES H, OH, CN, ALQUILO C1-C6, FENILO, COO-ALQUILO C1-C4; R4 ES H, HALOGENO, NH2, CN, ALQUILO C1-C6, FENILO, ALCOXILO C1-C6, BENCILO, BENZOILO, COO-ALQUILO C1-C6, HETEROCICLO; R5 ES H, OH, NH2, HALOGENO, ALQUILO C1-C6, CICLOALQUILO C3-C6, FENILO, PIRIDINILO, NH-ALQUILO C1-C4, N-CHN-ALQUILO C1-C4, EXCEPTO LOS COMPUESTOS PIRIDO[3,2-d]-PIRIMIDIN-2,4(1H,3H)-DIONA; 6-CLORO-2-METIL-4-OXO-PIRIDO[3,2-d]PIRIMIDINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y UN PROCESO PARA PREPARAR 7-TERBUTIL-6-(4-CLOROFENIL)-2-TIOXO-2,3-DIHIDRO-1.H-PIRIDO[2,3-d]-PIRIMIDIN-4-ONA. LOS COMPUESTOS SON BLOQUEADORES FUNCIONALES DEL RECEPTOR VANILOIDE HUMANO 1 (hVR1) Y PUEDEN SER UTILES COMO AGENTES ANTIHIPERALGESICOS Y PARA EL TRATAMIENTO DE OSTEOARTRITIS DOLOR POR CANCER, LESION MUSCULAR, FIBROMIALGIA
PE2002000241A 2001-03-26 2002-03-26 DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1) PE20021161A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0107505A GB0107505D0 (en) 2001-03-26 2001-03-26 Organic compounds
US33828101P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
PE20021161A1 true PE20021161A1 (es) 2003-02-21

Family

ID=26245894

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000241A PE20021161A1 (es) 2001-03-26 2002-03-26 DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1)

Country Status (17)

Country Link
US (1) US7915264B2 (es)
EP (1) EP1377576A2 (es)
JP (1) JP4205430B2 (es)
KR (1) KR20030083755A (es)
CN (1) CN1500089A (es)
BR (1) BR0208338A (es)
CA (1) CA2441599A1 (es)
CZ (1) CZ20032561A3 (es)
HU (1) HUP0303623A2 (es)
IL (1) IL157815A0 (es)
MX (1) MXPA03008754A (es)
NO (1) NO326546B1 (es)
PE (1) PE20021161A1 (es)
PL (1) PL363907A1 (es)
RU (1) RU2003130221A (es)
SK (1) SK11952003A3 (es)
WO (1) WO2002076946A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE393141T1 (de) 2000-08-21 2008-05-15 Pacific Corp Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
EP1311478B1 (en) 2000-08-21 2006-06-07 Pacific Corporation Novel (thio)urea compounds and the pharmaceutical compositions containing the same
WO2003062209A2 (en) 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
EP2033951A3 (en) 2002-02-01 2009-12-23 Euro-Celtique S.A. 2-Piperazine-pyridines useful for treating pain
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
JP4909068B2 (ja) 2003-02-14 2012-04-04 グラクソ グループ リミテッド カルボキサミド誘導体
JP5279987B2 (ja) 2003-05-20 2013-09-04 味の素株式会社 アミド誘導体
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20070135454A1 (en) 2003-11-14 2007-06-14 Tracy Bayliss Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006007851A2 (en) 2004-07-19 2006-01-26 Novo Nordisk A/S Capsaicin inhibitors for treating obesity and-related disorders
DE102004039373A1 (de) 2004-08-12 2006-02-23 Grünenthal GmbH Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
GB0506147D0 (en) * 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
US20090298856A1 (en) * 2005-05-11 2009-12-03 Rebecca Elizabeth Brown 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
CN103382176A (zh) * 2005-10-19 2013-11-06 格吕伦塔尔有限公司 新颖的辣椒素受体配体和它们用于生产药物的用途
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
KR100761222B1 (ko) * 2006-03-08 2007-10-04 성균관대학교산학협력단 약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
US8003656B2 (en) 2006-08-23 2011-08-23 Neurogen Corporation 2-phenoxy pyrimidinone analogues
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
CL2008001112A1 (es) * 2007-04-20 2008-12-19 Novartis Ag Usos de compuestos derivados de pirido[2,3-d]pirimidin-4-ona para tratar comezon o un trastorno relacionado con comezon; combinacion de los compuestos con otro farmaco; y uso de la combinacion para tratar la comezon o un trastorno relacionado con comezon.
MY147952A (en) * 2007-07-18 2013-02-15 Novartis Ag Synergistic combinations of vr-1 antagonists and cox-2 inhibitors
US8349846B2 (en) * 2008-01-11 2013-01-08 Glenmark Pharmaceuticals, S.A. Fused pyrimidine derivatives as TRPV3 modulators
WO2009121036A2 (en) * 2008-03-27 2009-10-01 Neurogen Corporation Substituted aryl pyrimidinone derivatives
US8362012B2 (en) 2008-04-18 2013-01-29 Daewoong Pharmaceutical Co., Ltd. Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
TW201348235A (zh) 2012-05-03 2013-12-01 Novartis Ag 作爲格瑞啉受體促效劑之3-螺環哌啶衍生物
EP3204347B1 (en) 2015-12-23 2024-10-23 Commonwealth Scientific and Industrial Research Organisation Enamine compounds for protecting against uv radiation
CN108863949B (zh) * 2018-07-09 2021-01-15 湖南博隽生物医药有限公司 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂及合成方法
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2749344A (en) * 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
IL112235A (en) 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

Also Published As

Publication number Publication date
NO326546B1 (no) 2009-01-05
MXPA03008754A (es) 2004-02-18
WO2002076946A3 (en) 2002-12-27
NO20034122D0 (no) 2003-09-16
US7915264B2 (en) 2011-03-29
IL157815A0 (en) 2004-03-28
CN1500089A (zh) 2004-05-26
NO20034122L (no) 2003-09-16
CZ20032561A3 (cs) 2003-12-17
RU2003130221A (ru) 2005-04-10
EP1377576A2 (en) 2004-01-07
BR0208338A (pt) 2004-03-09
PL363907A1 (en) 2004-11-29
HUP0303623A2 (hu) 2004-03-01
CA2441599A1 (en) 2002-10-03
SK11952003A3 (sk) 2004-03-02
US20040138454A1 (en) 2004-07-15
JP4205430B2 (ja) 2009-01-07
KR20030083755A (ko) 2003-10-30
JP2004528312A (ja) 2004-09-16
WO2002076946A2 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
PE20021161A1 (es) DERIVADOS DE PIRIDINA COMO BLOQUEADORES DEL RECEPTOR VANILOIDE (hVR1)
RU2376287C2 (ru) Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac
RU2010150818A (ru) Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
CY1109263T1 (el) Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine
PE20020976A1 (es) Pirido-pirimidinas 6-sustituidas como inhibidores de quinasas
MXPA04003474A (es) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a.
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20020062A1 (es) 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a
AP2002002586A0 (en) Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.
JP2004525149A5 (es)
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
CY1107807T1 (el) Παρaγωγα πυριμιδiνης
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
PL207340B1 (pl) Związki imidazochinolinowe, środek farmaceutyczny i ich zastosowanie
CA2416274A1 (en) N-phenyl-2-pyrimidine-amine derivatives
YU55603A (sh) Derivati purina kao antagonisti purinergiskog receptora
RU2004106783A (ru) Производные 4-амино-6-фенилпирроло[2, 3] пиримидина
JP2004525868A (ja) 置換イミダゾピリジン類
JP2004505964A5 (es)
JP2005508966A5 (es)
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
PE20030129A1 (es) Imidazotriazinas
RU2009113612A (ru) Ацетамидные производные хиназолинона и изохинолинона
RU2012144751A (ru) Гетероциклические соединения, эффективные для ингибирования киназы
PE20010401A1 (es) DERIVADOS DE 8-FENIL-6,9-DIHIDRO-[1,2,4] TRIAZOL [3,4-i] PURIN-5-ONA COMO INHIBIDORES DE FOSFODIESTERASA ESPECIFICA DE GMP CICLICO

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed